The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
On April 14th Trinity stated
"The months
following CE Marking should see further commercialisation agreements addressing
Latin America, Middle East, and European markets. "
So now the CE mark is there should see a cascade of deals.
You are right the CE mark came sooner than expected,we have just had a bank holiday weekend and so now should be all systems go.
The co already told us initial offers have been received and there was strong interest.
Liberum said the following last friday.
" the company is now well positioned to sign larger commercialisation
deals."
Interesting how booth chooses to try and pout a negative spin on every post
This is what was actually written and the article was titled
Singin the Bulls
Futura Medical (LON:FUM) might at very long last be on the brink of commercial proceeds for its erectile dysfunction gel. If these emerge, anything below 100p will make FUM look very cheap. And possibly desirable to a formally registered ceiling inspector seeking a log in.
"Futura Medical (LON:FUM) might at very long last be on the brink of commercial proceeds for its erectile dysfunction gel. If these emerge, anything below 100p will make FUM look very cheap. And possibly desirable to a formally registered ceiling inspector seeking a log in."
Forget your interpretation this is what was actually written
You are right Lombard bought more CFDs
1,468,367 from 1,399,531
You need to ask yourself that question.
I see your new venture is supplying part time Finance directors.
Hysterical
Are you sayinghe is the former finance director full of resentment because he has no shares?
From the co's website
Strong IP
DermaSys® is a proprietary transdermal technology platform with very strong IP offering a high level of product differentiation compared to existing marketed treatments.
Each new unique formulation offers the opportunity for additional patent applications and potential patent protection. We protect this valuable IP and ensure that we maximise both the strength of our patents’ protection and their duration. Aside from our current patent lawyers, Futura recently retained a specialist biotech IP and strategic advice company to assist in maximising the robustness of the MED3000 intellectual property.
email market.abuse@fca.org.uk
All formulations tested in FM57, including MED3000, have demonstrated positive and statistically significant efficacy results against baseline data together with excellent safety profile. MED3000 will be of high interest to the Medical Community for those patients who are seeking a very rapid onset of action and a very low side-effect profile. It will likely find use in the substantial number of patients, especially those with ED of a mild to moderate nature and those patients who are contraindicated for use with existing products.
Dr Yacov Reisman
Consultant Urologist and past president of the European Society of Sexual Medicine
Again couldn't be clearer
The efficacy of MED3000 is remarkable and approaches the efficacy of current first line therapy but with significantly lower adverse events. With topical application, it will be of particular appeal to patients who want a fast onset of action. Lack of drug interactions with prescription products will enable the product to be used with other medications such as nitrates and other cardiovascular drugs. It can also be used in conjunction with other ED products to improve overall efficacy to patients. As such MED3000 will be of great interest to the medical community.”
Professor David Ralph
Consultant Urologist at University College London and past president of the European Society of Sexual Medicine
It couldn't be clearer
Lambooth also failed to mention the elephant in the room
"formulated into an enhanced absorption topical delivery system (DermaSys)."
People with ED will not get any effect from rubbing KY jelly for just 15 second on the tip of the *****.
I dont have ED and I dont get any effect rubbing KY jelly for just 15 seconds either.
If you had ever had sex you might understand.
Med3000 has a CE mark and if you have a look on then web you will see the packaging which says clinically proven and fast acting.
Lamebooth lost his house and is so bitter its pathetic
"The same broker that said the Phase 3 trial for MED2002 was “low-risk” as the study currently had 20 realistic outcomes, only one of which would mean the treatment could not be launched commercially."
Update
EU CE mark received
Well we will see it on he shelves in weeks.
Liberum were spot on
You are so so so angry
Hahahahaha
Peter Lynch one of the world's greatest investors,you are so right.
This is the world's first topically applied OTC product clinically proven to treat ED with a fast acting mode of action.
Will reach blockbuster status of over $1billion sales very quickly
Viagra reached that in it's first year of launch and that was prescription only,in a time the internet was in it's infancy and social media didn't exist.
He said and He said
The efficacy of MED3000 is remarkable and approaches the efficacy of current first line therapy but with significantly lower adverse events. With topical application, it will be of particular appeal to patients who want a fast onset of action. Lack of drug interactions with prescription products will enable the product to be used with other medications such as nitrates and other cardiovascular drugs. It can also be used in conjunction with other ED products to improve overall efficacy to patients. As such MED3000 will be of great interest to the medical community.”
Professor David Ralph
Consultant Urologist at University College London and past president of the European Society of Sexual Medicine
He said and he said
Erectile dysfunction often becomes a barrier to spontaneity and intimacy in a relationship, which harms both the man and his partner over time. A product -such as MED3000 - that can be applied as part of foreplay could help to break down the barriers that have proved so difficult to overcome with existing treatments.”
Ian Eardley
Consultant Urologist
Past President of the European Society of Sexual Medicine
Department of Urology, St James University Hospital, Leeds
He said and he said
All formulations tested in FM57, including MED3000, have demonstrated positive and statistically significant efficacy results against baseline data together with excellent safety profile. MED3000 will be of high interest to the Medical Community for those patients who are seeking a very rapid onset of action and a very low side-effect profile. It will likely find use in the substantial number of patients, especially those with ED of a mild to moderate nature and those patients who are contraindicated for use with existing products.
Dr Yacov Reisman
Consultant Urologist and past president of the European Society of Sexual Medicine
Whole new market opened up
Study: Erectile Dysfunction Is 5 Times More Likely in Men Who've Had COVID-19
https://www.verywellhealth.com/erectile-dysfunction-frequency-covid-5180016